Soluble Triticain-Alpha Production via Optimized Expression and Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant triticain-alpha, a wheat cysteine protease, result in low activity, yield, and purity, making them unsuitable for therapeutic and research applications, particularly in treating celiac disease.
Innovation Solution
A method for producing a highly purified and active fragment of triticain-alpha in soluble form using recombinant expression in bacterial and yeast systems, involving specific plasmids and expression vectors, and a chromatographic purification process that eliminates the need for refolding, resulting in high yield and purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant triticain-alpha is produced using conventional methods, then the protein is obtained, but the activity, yield, and purity are low
Solution Approach 1:
The patent optimizes expression parameters including induction temperature (18-25°C), induction time (16-24 hours), and IPTG concentration (0.5-1.0 mM) to maximize soluble protein production. The purification parameters are also optimized with specific buffer compositions and chromatography conditions to achieve high purity and activity
Solution Approach 2:
The patent uses a polyhistidine tag as an intermediary element that facilitates purification through nickel-nitrilotriacetic acid (Ni-NTA) affinity chromatography. This tag acts as a mediator between the recombinant protein and the purification matrix, enabling high purity isolation without compromising enzyme activity
2Ease of manufacture
If conventional purification methods are used, then the protein is isolated, but additional refolding steps are required and the process is complex
Solution Approach 1:
The patent extracts the problematic refolding step from the purification process by ensuring the protein remains in soluble form throughout expression and purification. This eliminates the need for separate refolding operations and reduces overall process complexity
Solution Approach 2:
The Ni-NTA affinity chromatography system serves multiple functions: it binds the polyhistidine-tagged protein, allows removal of contaminants in one step, and maintains protein in active soluble form. This multi-functional approach simplifies the purification workflow
3Productivity
If the protein is produced in insoluble form, then expression yield may be high, but refolding is required which reduces activity and increases process complexity
Solution Approach 1:
The patent changes the physical state parameter of the expressed protein from insoluble to soluble by optimizing expression conditions including lower induction temperatures (18-25°C versus higher temperatures) and extended induction times (16-24 hours). These parameter changes maintain high expression yield while ensuring the protein remains in active soluble conformation
Solution Approach 2:
The patent takes preliminary action by designing the expression system to produce soluble protein from the outset, preventing the formation of insoluble aggregates. This preliminary consideration of solubility in the expression design eliminates the need for subsequent refolding operations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves a highly active and purified triticain-alpha preparation, suitable for therapeutic and research use, with specific activity exceeding previous methods and simplifying the production process.
Implementation Method 1
The corresponding supernatant obtained after centrifugation of lysates is applied onto a column with nickel-activated iminodiacetate-sepharose equilibrated in buffer A, the sorbent is washed successively with the equilibrated buffer A, then the protein is eluted with buffer A containing 0.3 M imidazole
Data Source
AI summary
The invention relates to the field of molecular biology, preparative biochemistry, biotechnology, and biopharmacology, namely to the creation of recombinant proteins of the family of wheat (Triticum aestivum) cysteine proteases in soluble form, and preparations of the protein triticain-alpha consisting of a fragment of wheat triticain-alpha and methods for the production thereof. The invention can be used for research purposes to study the functioning of papain-like cysteine proteases, as well as in medicine for developing therapeutic enzyme preparations, and is a method of producing, in soluble form, recombinant functionally active variants of wheat (Triticum aestivum) cysteine proteases, including the engineering of plasmid DNA for cloning in expression systems of E. coli and P. Pastoris. By transforming cells of E. coli of the strain Rossetta gami B (DE3) and cells of P. pastoris of the strain GS115 by plasmid DNA pET15-6HIS-tritcain-α-GM, pET15-triticain-α-GM-6HIS, and pPIC9-triticain-α-GM respectively, truncated producing strains of wheat triticain-alpha are obtained, with subsequent culturing of host cells, separation of expressing protein, and purification by chromatographic methods. The invention allows variants of a biologically active fragment of wheat protease to be produced in soluble form in bacteria and yeast expression systems and allows the preparation triticain-alpha to be produced with a high, stable output, purity level and functional activity.